Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifapentine and Moxifloxacin for Intensive Phase Pulmonary Tuberculosis
NCT00728507Phase 2Terminated
- Sponsor
- Johns Hopkins University
- Start
- Nov 2009
- Primary completion
- Apr 2013
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rifapentine and moxifloxacin in Tuberculosis (TB), sponsored by Johns Hopkins University. Started Nov 2009; status: terminated.
02
Drugs
rifapentinemoxifloxacin
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT00728507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00728507.